In a cohort of more than 153 k people with COVID-19, 5.6 million contemporary controls, and 5.8 million historical controls without evidence of infection
We show increased risks of a wide range of cardiovascular diseases at 1 year
These include cerebrovascular disorders, dysrhythmias, ischemic and non-ischemic heart disease, pericarditis, myocarditis, heart failure and thromboembolic disease.
The risks of cardiovascular diseases were evident in all subgroups: young and old, White and Black people, males and females, and several other subgroups
The risks were evident in people who had no prior history of any cardiovascular disease
The risks were evident even among people who did not need hospitalization or ICU care during the acute phase of SARS-CoV-2 infection
Governments and health systems around the world should be prepared to deal with the likely significant contribution of the COVID-19 pandemic to a rise in the burden of cardiovascular diseases
Because of the chronic nature of these conditions, they will likely have long-lasting consequences for patients and health systems and also have broad implications on economic productivity and life expectancy
Addressing the challenges posed by Long COVID will require a much needed, but so far lacking, urgent and coordinated long-term global response strategy
Most grateful to the #LongCovid patient community whose heroic and historical advocacy inspired us and continue to inspire us to work very hard on #LongCovidResearch
#Longcovid is a multifaceted disease; it can affect multiple organ systems including respiratory, cardiovascular, nervous, mental health, metabolic, gastrointestinal, kidneys, and other organ systems.
People with #longcovid have increased risk of incident use of several therapeutics including pain medications (opioids and non-opioids), antidepressants, anxiolytics, antihypertensives, and oral antihyperglycemics and evidence of laboratory abnormalities in multiple organ systems